CORONA - SARS-CoV-2-VLP-IVD - Development of a certified in vitro diagnostic (IVD) for the reliable determination of COVID-19-specific immune responses in human serum; subproject 5: Establishment of a biobank, comparative measurements and preparation of international distribution

Within the scope of the subproject, a biobank with well-characterized samples is to be established and ultimately international distribution is to be undertaken. By linking Wimedko to MeoClinik - Berlin's largest private practice with 40,000 patients per year - approximately 6,000 serum samples will be collected and archived for test development, validation and approval. The serum samples will be analyzed in-house with EuroImmun's ELISA kit and compared with the results of the new Roche test (Berlin laboratory). The final step is the joint validation and approval study of the newly developed VLP ELISA with CellTrend. Dr. Julian Kamhieh-Milz and Dr. Omar Kamal have a broad network at their disposal, through which the international distribution of the final product can be realized.